Head-to-head

CJC-1295 vs Tesamorelin

A field-by-field comparison of CJC-1295 and Tesamorelin drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as growth hormone compounds, so the useful question is how they differ within that category.

CJC-1295 vs Tesamorelin: editorial summary

CJC-1295 and tesamorelin are both GHRH analogues, making this a much closer mechanistic comparison than many other peptide pairings. Both act on the GHRH pathway to stimulate endogenous growth-hormone secretion, but their molecular structures, pharmacokinetics, evidence bases and regulatory status differ.

Key considerations

Tesamorelin is a stabilised 44-amino-acid GHRH analogue with an FDA-approved indication. CJC-1295 is a 30-amino-acid GHRH analogue that exists in DAC and no-DAC forms and is not FDA-approved.
The distinction between the two CJC-1295 forms is especially important when comparing pharmacokinetics: the DAC version is substantially longer-acting than the no-DAC form.

CJC-1295 characteristics

CJC-1295 is a GHRH analogue with Moderate evidence and distinct DAC/no-DAC pharmacokinetic profiles.

Tesamorelin characteristics

Tesamorelin is a stabilised GHRH analogue with Strong evidence and a specific FDA-approved indication.

CJC-1295 vs Tesamorelin at a glance

Attribute	CJC-1295	Tesamorelin
Category	Growth hormone	Growth hormone
Evidence grade	Moderate	Strong
Also known as	Modified GRF 1-29, DAC:GRF	Egrifta, TH9507
Chain	30 amino acid GHRH analogue	44 amino acid stabilised GHRH analogue
Mechanism	Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week.	A stabilised GHRH(1-44) analogue that resists enzymatic degradation, producing a sustained, physiological increase in endogenous GH and downstream IGF-1.
Reported benefits	Elevated GH and IGF-1 across the dosing window · Improved sleep depth reported by most users · Supports lean mass retention and fat oxidation	Clinically demonstrated visceral adipose tissue reduction (~15–18%) · Improved triglycerides in trial populations · Preliminary evidence for cognitive benefit in older adults
Reported side effects	Water retention · Tingling or numbness in hands · Head rush and flushing after injection · Elevated fasting glucose at higher doses	Joint pain and swelling · Injection-site erythema · Insulin resistance · Peripheral oedema
Half-life	~30 minutes without DAC; ~6–8 days with DAC	26–38 minutes
Administration	Subcutaneous injection, typically before bed on an empty stomach	Daily subcutaneous injection, abdomen
Dosing overview	100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version	Approved label dose is 2 mg once daily
Storage	Refrigerate reconstituted product; protect from light and avoid shaking	Refrigerated; reconstitute immediately before use per label
Legal status	Not FDA-approved. Prescribed off-label by some clinics; banned in sport.	FDA-approved for a specific indication; other uses are off-label.

Key differences between CJC-1295 and Tesamorelin

Both are growth hormone compounds

CJC-1295 and Tesamorelin are both indexed under growth hormone, so they compete for the same use case rather than complementing each other. CJC-1295: "A growth-hormone-releasing hormone analogue that raises the baseline of natural GH output rather than replacing it." Tesamorelin: "The one GH-axis peptide with full FDA approval, indicated for reducing excess visceral abdominal fat in HIV-associated lipodystrophy."

Mechanism of action

CJC-1295: Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week. Tesamorelin: A stabilised GHRH(1-44) analogue that resists enzymatic degradation, producing a sustained, physiological increase in endogenous GH and downstream IGF-1.

Evidence quality is not equal

CJC-1295 carries a Moderate evidence grade and Tesamorelin a Strong grade on this index. The grade describes the quality of published human data, not how well a compound works — Tesamorelin has the better-documented record of the two, and claims made about CJC-1295 rest on thinner human evidence.

Half-life and dosing frequency

CJC-1295 is listed at ~30 minutes without dac; ~6–8 days with dac; Tesamorelin at 26–38 minutes. That difference is what drives the reported schedules: 100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version versus Approved label dose is 2 mg once daily

Route of administration

CJC-1295 is administered by subcutaneous injection, typically before bed on an empty stomach. Tesamorelin is administered by daily subcutaneous injection, abdomen.

Legal and regulatory status differs

CJC-1295: Not FDA-approved. Prescribed off-label by some clinics; banned in sport. Tesamorelin: FDA-approved for a specific indication; other uses are off-label. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

CJC-1295 is stored refrigerate reconstituted product; protect from light and avoid shaking. Tesamorelin is stored refrigerated; reconstitute immediately before use per label.

What CJC-1295 and Tesamorelin have in common

Category: both listed as Growth hormone

Each compound in brief

CJC-1295

Growth hormone · Moderate evidence

A growth-hormone-releasing hormone analogue that raises the baseline of natural GH output rather than replacing it.

Considerations: Usually paired with a GHRP such as Ipamorelin for a synergistic pulse · No-DAC (Mod GRF 1-29) suits pulsatile dosing; DAC suits steady elevation · GH elevation is not desirable for everyone — screen for cancer history

Tesamorelin

Growth hormone · Strong evidence

The one GH-axis peptide with full FDA approval, indicated for reducing excess visceral abdominal fat in HIV-associated lipodystrophy.

Considerations: Visceral fat returns after discontinuation · Requires monitoring of fasting glucose and IGF-1 · Expensive relative to other GH secretagogues

Frequently asked questions

Do CJC-1295 and tesamorelin use the same pathway?

Yes. Both are GHRH analogues and act through the growth-hormone-releasing-hormone pathway.

What is the biggest difference between them?

Tesamorelin has an approved medical indication and a more established clinical evidence base, while CJC-1295 remains unapproved and is available in distinct DAC and no-DAC forms.

Is CJC-1295 the same as tesamorelin?

No. They are different GHRH analogues with different molecular structures and pharmacokinetic properties.